These five Dow Jones industrial companies have paid dividends to shareholders for at least 100 years, perfect ideas for ...

TD Cowen has lowered Eli Lilly’s price target from $1,050 to $960, but maintained a Buy rating, citing solid long-term ...

Erste Group has downgraded Eli Lilly from a buy to a hold rating due to concerns about its earnings forecast. Despite 36.38% ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful ...

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to ...

Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Eli Lilly: "I just think this is a decent level to start a position if you don't have any [buy, buy, buy!]." Navitas: "That one's done...I say take your money out that you put in and then you can ...